Press releases.

Press releases 2021

Press releases 2021
October 12th 2021

2021 Annual General Meeting and Key Dates

October 4th 2021

Immutep to present Phase II TACTI-002 data at SITC 2021

September 29th 2021

Immutep Receives A$3.4 million R&D French Tax Incentive

September 28th 2021

Immutep to Present at Healthcare Investor Conferences

September 21st 2021

Immutep to present final Overall Survival data from Phase IIb AIPAC as a Late Breaking Poster Presentation at SITC 2021

September 1st 2021

Immutep Completes Recruitment of 2nd line PD-1/PD-L1 refractory NSCLC Patients in TACTI-002

August 31st 2021

Immutep's Partner, EOC Pharma, Expands Efti Trial Pipeline

August 27th 2021

Immutep Announces Chinese Patent Grant for LAG-3 Antagonist Antibody LAG525

August 5th 2021

INSIGHT-003 investigator-initiated trial - 1st patient dosed

July 26th 2021

Results of EGM

July 21st 2021

Completion of Share Purchase Plan

July 13th 2021

Immutep Quarterly Activities Report & Appendix 4C

July 6th 2021

Immutep receives FDA and IRB approval in the US for Phase IIb TACTI-003 trial in HNSCC

June 21st 2021

Immutep secures commitments for A$60 million through a two-tranche institutional placement to expand its clinical development and manufacturing program into late-stage settings

June 21st 2021

Immutep to Evaluate Efti in Triple Combination Therapy Phase I Study with Chemotherapy and an anti-PD-1 Therapy

June 8th 2021

Immutep Reveals a New anti-LAG-3 Research Program

June 4th 2021

Immutep Reports Positive Data from its TACTI-002 Phase II Study of LAG-3 Therapy, Efti, at ASCO 2021

June 4th 2021

Immutep Reports Positive Final Data from the INSIGHT-004 Phase I Study of LAG-3 Therapy, Efti, at ASCO 2021

June 2nd 2021

Immutep Secures Second European Patent For Eftilagimod Alpha, A Soluble LAG-3 Protein, In Combination With A PD-1 Pathway Inhibitor

June 1st 2021

Immutep Enters into a New Collaboration with Merck KGaA, Darmstadt, Germany for LAG-3 Therapy, Efti

May 26th 2021

Immutep Granted Chinese Patent for Eftilagimod Alpha in Chemo-Immunotherapy Combination

May 25th 2021

Immutep to Present at the Jefferies Virtual Healthcare Conference

May 7th 2021

Immutep Operational Update

April 29th 2021

Immutep To Announce New TACTI-002 and INSIGHT-004 Data in Poster Presentations and Discussion at the ASCO 2021 Annual Meeting

April 19th 2021

Immutep Quarterly Activities Report & Appendix 4C

April 16th 2021

Immutep Receives A$1,155,055 R&D Tax Incentive

April 8th 2021

Immutep Achieves Fast Track Designation From US FDA For Efti, A Soluble Lag-3 Protein, In First Line Recurrent/Metastatic Head & Neck Cancer

April 7th 2021

Immutep Announces European Patent Grant For LAG525 Antibody In Combination Therapy

March 16th 2021

Immutep Enters Second Collaboration with MSD for a New Randomised Phase IIB Trial in Head and Neck Cancer

March 9th 2021

Immutep Secures Second United States Patent Grant For Eftilagimod Alpha In Combination With A PD-1 Pathway Inhibitor

March 5th 2021

Immutep Expands Part B of TACTI-002 Collaboration Trial

January 27th 2021

Immutep Announces Advancement Of Phase II Trial For Eftilagimod Alpha In Covid-19 Patients To Randomised Portion Of The Study

January 22nd 2021

Immutep Quarterly Activities Report & Appendix 4C

January 22nd 2021

Ulcerative Colitis Phase II Study of GSK2831781 Discontinued

January 7th 2021

Immutep Completes Recruitment of Head and Neck Cancer Patients of Phase II TACTI-002 Study